Skip to content
Screener

Charles River Laboratories CRL Total Cost of Revenue

Discontinued — last reported Q3 '24

Total Cost of Revenue at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$2.62B+5.6%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$7.63M+12.2%
Sotera Health logo
Sotera HealthSHC
$143.41M+12.3%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$1.72M-68.0%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$539M-6.6%
Revvity logo
RevvityRVTY
$323.46M+11.8%

Segments

By segment

See full
DSA$412.34M-2.3%
RMS$143.83M+0.5%
Manufacturing$84.54M-23.2%

By product

See full
Cost of services provided (excluding amortization of intangible assets)$552.01M-5.6%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%
Operating margin13%-2.4pp
Net margin-6%
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Charles River Laboratories’s 10-Q, filed November 6, 2024.

Filed
Nov 6, 2024
Fiscal quarter
Q3 FY2024
Calendar quarter
Q3 2024
Accession
0001100682-24-000035
Line itemThree Months Ended / September 28, 2024Three Months Ended / September 30, 2023Nine Months Ended / September 28, 2024Nine Months Ended / September 30, 2023
Operating income (1)$(76,763)$(49,918)$(196,357)$(165,886)
Consolidated
Revenue$1,009,763$1,026,623$3,047,440$3,115,933
Cost of revenue (excluding amortization of intangible assets)660,742664,7831,999,8631,977,462
Selling, general and administrative199,213176,109555,295550,713
Amortization of intangible assets32,40334,22997,248103,419
Operating income$117,405$151,502$395,034$484,339
(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's total cost of revenue?
Charles River Laboratories (CRL) reported total cost of revenue of $660.74M in Q3 2024.
How has Charles River Laboratories's total cost of revenue changed year-over-year?
Charles River Laboratories's total cost of revenue decreased by 0.6% year-over-year, from $664.78M to $660.74M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Charles River Laboratories's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude